U.S. markets open in 2 hours 40 minutes
  • S&P Futures

    3,862.00
    +42.75 (+1.12%)
     
  • Dow Futures

    31,968.00
    +192.00 (+0.60%)
     
  • Nasdaq Futures

    12,583.00
    +285.75 (+2.32%)
     
  • Russell 2000 Futures

    2,232.80
    +32.00 (+1.45%)
     
  • Crude Oil

    65.91
    +0.86 (+1.32%)
     
  • Gold

    1,705.60
    +27.60 (+1.64%)
     
  • Silver

    25.85
    +0.59 (+2.32%)
     
  • EUR/USD

    1.1912
    +0.0059 (+0.50%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.40
    -0.26 (-1.05%)
     
  • GBP/USD

    1.3883
    +0.0061 (+0.44%)
     
  • USD/JPY

    108.7400
    -0.1610 (-0.15%)
     
  • BTC-USD

    54,139.34
    +3,899.18 (+7.76%)
     
  • CMC Crypto 200

    1,092.97
    +68.77 (+6.71%)
     
  • FTSE 100

    6,781.16
    +62.03 (+0.92%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

FLORHAM PARK, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief Executive Officer, and Azmi Nabulsi, M.D., Chief Operating Officer, will present at Cowen and Company’s 40th Annual Healthcare Conference in Boston on March 2, 12:00 pm EST at the Boston Marriott Copley Place.

To access the live webcast and archived recordings for this presentation, visit the Investors & Media section of the Phathom Pharmaceuticals website at www.phathompharma.com.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at www.phathompharma.com.

Follow Phathom on LinkedIn at www.linkedin.com/company/phathompharma.

CONTACTS

Media Contacts:
Joe Hand
1-877-742-8466
info@phathompharma.com

Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Patti Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com